Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-353-1 | CAS number: 464-45-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Skin sensitisation (in chemico): Weight of evidence. Test method according to the OECD 442C Guideline with GLP. The test item showed a mean depletion of lysine and cysteine peptides of 1.13%, reflecting no or minimal reactivity and thus a negative prediction of DPRA.
Skin sensitisation (in vitro): Weight of evidence. Test method according to the OECD 442D Guideline with GLP. Under the experimental conditions the test item L-borneol may be classified as not skin sensitizer using the KeratinoSensTM test method.
Skin sensitisation: Weight of evidence. integrated testing strategy (ITS). Based on the“2 out of 3-sens ITS” approach as described in annex 1 of OECD guidance ENV/JM/MONO(2016)29, two negative results obtained in the tests addressing two different key events (KEs) means that L-borneol does not need to be classified as skin sensitizer.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 10 April 2017 - 13 April 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- direct peptide reactivity assay (DPRA)
- Details on the study design:
- Details on study design:
ITEM SOLVENT
Initial election of test item solvent: solubility of the test item in an appropriate solvent was assessed before performing the assay. The chosen solvent was acetonitrile.
TEST SYSTEM
Cysteine peptide (supplier RS Synthesis, LLC; Ref. Ac RFAACAA-COOH; batch no 160801; purity 94.82%)
Lysine peptide (supplier RS Synthesis, LLC; Ref. Ac-RFAAKAA-COOH; batch no 160801; purity 94.19%)
CONTROLS
Positive control: cinnamaldehyde (CAS 104-55-2; batch no MKBT8955V; purity 99.1%)
Co-elution control: test item in phosphate buffer (100 mM; pH 7.5 ± 0.05) for cysteine peptide and ammonium acetate buffer (100 mM; pH 10.2 ± 0.05) for lysine peptide.
Reference control A: prepared with acetonitrile in order to check the calibration curve accuracy.
Reference control B: prepared with acetonitrile and included at the beginning and at the end of the sequence in order to check the stability of peptide over time.
Reference control C: prepared with acetonitrile, the test item and the positive control solvent, in order to check its influence on the peptide stability.
PREPARATION OF THE TEST ITEM AND POSITIVE CONTROL SOLUTIONS
Test item solution: 47.2 mg was pre-weighted in a glass vial in order to prepare, right for use, 3 ml of a limpid 100 mM solution with acetonitrile.
Positive control solution: 38.2 µl of the positive control were distributed in a 5 ml glass vial in order to prepare, right before use, 3 ml of a limpid 100 mM solution with acetonitrile.
PREPARATION OF THE PEPTIDE SOLUTIONS
Peptide solutions were prepared at 0.667 mM:
Cysteine solution: 11 mg of cysteine peptide were pre-weighted then dissolved, right before the incubation, in 22 ml of phosphate buffer (100 mM; pH 7.5 ± 0.05).
Lysine solution: 14.8 mg of lysine peptide were pre-weighted then dissolved, right before the incubation, in 28,6 ml of ammonium acetate buffer (100 mM; pH 10.2 ± 0.05).
TEST SOLUTIONS
Samples were dissolved immediately before use (100 mM positive control solution was kept for the 2 runs).
Peptides were incubated with each sample (test item and positive control) at 1:10 and 1:50 ratio for cysteine and lysine respectively.
All the replicates were prepared with the same peptide stock solutions.
1 ml of each solution was prepared according to the following quantities:
Cysteine test solution (0.5 mM Peptide, 5 mM Sample): 750 µl of cysteine peptide solution (buffer only to check co-elution) + 50 µl of sample or solvent for Reference controls + 200 µl of acetonitrile.
Lysine test solution (0.5 mM Peptide, 25 mM Sample): 750 µl of lysine peptide solution (buffer only to check co-elution) + 250 µl of sample or solvent for Reference controls.
The vials were capped and mixed carefully avoiding bubbling, then placed in the HPLC system sampler at 25°C ± 2.5°C. HPLC analysis started 24 hours ± 2 hours after addition of peptides.
Immediately upon addition of the test item solution to the peptide solution, just prior the beginning of the HPLC analysis and at the end of the analysis, samples were checked. No precipitate was observed.
Replicates: Each sample was tested 3 times from 3 independent solutions
HPLC ANALYSIS
-Apparatus: Waters e2695 HPLC; Waters 2489 UV detector; Cortecs column C18 2.7 µm ; dimensions 2.1 x 100 mm
-Calibration curve: Six peptides standards solutions between 0.534 mM and 0.0167 mM (dilution factor 2) were prepared in 20% acetonitrile in phosphate buffer for cysteine peptide and ammonium acetate for lysine peptide. The dilution buffer was also included as blank in the standard calibration curve.
-Equilibration of the column: at 30°C with 50% phase A (0.1% (v/v) trifluoroacetic acid in water) and 50% phase B (0.085% (v/v) trifluoroacetic acid in acetonitrile) for at least 20 minutes before running.
-Volume injected: 7 µl of each sample
-Flow rate: 0.21 ml/min
-Sequence (gradient): see table 1 on “Any other information on materials and methods incl. tables”
-Duration of re-equilibration to the initial conditions between injections: at least 4 min.
-Analysis sequence:
The analysis was programmed according to the following principles:
The reference controls B were placed at the beginning and at the end of the analysis (3 repetitions).
The reference controls C were placed at the beginning of each repetition.
The standards of the calibration curve and the reference controls A were placed in order to be analyzed progressively throughout the sequence.
Lysine and cysteine analysis were conducted on separate day and test item was freshly prepared for both assays on each day. The analysis was timed to assure that the injection of the first sample starts 22 to 26 hours after the test item was mixed with the peptide solution. The HPLC analysis time was less than 30 hours.
DEVIATIONS FROM OECD GUIDELINE: No.
The column used has 2.7 µm particle size when the column described in the OECD 442C has 3.5 µm particle size. According to the guideline, the set-up parameters were adjusted to guarantee an appropriate elution and integration of the cysteine and lysine peptides. Proficiency substances recommended in the OECD guideline were performed in these conditions. - Positive control results:
- The depletion mean rate was 73.86% for cysteine peptide and 55.56% for lysine peptide.
- Key result
- Run / experiment:
- other: mean of 3 repetitions
- Parameter:
- other: %depletion in lysine peptide
- Value:
- 0.97
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: Mean of 3 repetitions
- Parameter:
- other: %depletion in cysteine peptide
- Value:
- 1.29
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: Mean of lysine and cysteine peptides
- Parameter:
- other: mean %depletion in peptides
- Value:
- 1.13
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- OTHER EFFECTS:
- Visible damage on test system: No
DEMONSTRATION OF TECHNICAL PROFICIENCY: yes, the 10 proficiency substances recommended in the OECD guideline 442C were performed, obtaining values that fall within the respective reference range for 8 out of the 10 for each peptide.
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for calibration curve: yes, coefficient r2 was higher than 0.99 for lysine and cysteine.
- Acceptance criteria met for reference control A: yes, the mean concentration of peptide was 0.511 mM for lysine and 0.502 mM for cysteine which are equal to 0.50± 0.05 mM
- Acceptance criteria met for reference control B: yes, the CV (coefficient of variation) of the controls B was 0.86% which is lower than 15%.
- Acceptance criteria met for reference control C: yes, the mean concentration of peptide was 0.516 mM for lysine and 0.496 mM for cysteine which are equal to 0.50± 0.05 mM. The CV (coefficient of variation) of the controls C was 1.16% which is lower than 15%.
- Acceptance criteria met for positive control: Yes, SD of the 3 repetitions for each peptide was 0.243% for cysteine and 0.43% for lysine which are lower than 14.9% and 11.6% for cysteine and lysine respectively. The depletion mean rate was 73.86% for cysteine peptide and 55.56% for lysine peptide which are between 60.8% and 100% for the cysteine and between 40.2% and 69.4% for the lysine.
- Acceptance criteria met for variability between replicate measurements: Yes, SD of the 3 repetitions of the test item for each peptide was 1.13% for cysteine and 0.78% for lysine which are lower than 14.9% and 11.6% for cysteine and lysine respectively. - Interpretation of results:
- other: DPRA test result is considered in an overall weight of evidence assessment, i.e. as part of an integrated approach to testing and assessment (IATA) in accordance with OECD guideline 442C.
- Conclusions:
- The test item shows mean depletion of 0.97% for lysine and 1.29% for cysteine, i.e. an overall average of 1.13%, reflecting no or minimal reactivity and thus a negative prediction of DPRA skin sensitization test.
- Executive summary:
A DPRA skin sensitization test was performed for L-borneol as part of an integrated approach to testing and assessment (IATA) in accordance to OECD guideline 442C, under GLP conditions. The test item and Cinnamaldehyde (positive control) were prepared at 100 mM in acetonitrile as solvent. Reference controls A, B and C were prepared with acetonitrile in order to check the HPLC system suitability, the stability of peptide over time and the influence of the solvent on the peptide depletion respectively. Peptide solutions were prepared at 0.667 mM in phosphate buffer for cysteine and ammonium acetate buffer for lysine. Test item and positive control were incubated for 24 hours ± 2 hours at 25°C ± 2.5°C with the peptides solutions at 1:10 and 1:50 ratio for cysteine and lysine respectively, before HPLC analysis. Each sample was tested 3 times from 3 independent solutions. All validity criteria were fulfilled. The test item shows mean depletion of 0.97% for lysine and 1.29% for cysteine, i.e. an overall average of 1.13%, reflecting no or minimal reactivity and thus a negative prediction of DPRA.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 18 April 2017 - 28 April 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
- Deviations:
- yes
- Remarks:
- Dilution strategy (see justification on "details on study design")
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- activation of keratinocytes
- Details on the study design:
- Details on study design:
REAGENTS AND MEDIA
-DMSO (Supplier ref. D5879-1L, Sigma Aldrich; Batch no SZBG2170; purity ≥99.5%)
-DMEM 1 g/l glucose (Supplier ref. 21885025, Fisher Bioblock; Batch no 1852416)
-Non-heat inactivated foetal calf serum (Supplier ref. 10270098, Fisher Bioblock; Batch no 42Q9761K)
-Maintenance medium: DMEM 1 g/l glucose, 9.1% non-heat inactivated foetal calf serum, 0.05% geneticin.
-Seeding medium: DMEM 1 g/l glucose, 9.1% non-heat inactivated foetal calf serum.
-Treatment medium: DMEM 1 g/l glucose, 1% non-heat inactivated foetal calf serum.
-Staining solution: 5 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) solution in PBS (phosphate buffered saline). Prepared extemporaneously and used within the day.
TEST SYSTEM
-Cells: KeratinoSens™ (Givaudan)
-Culture: cells were cultured at 37ºC, 5% CO2 in maintenance medium.
-Passage number: cells were used at passage 25 in repetition 1 and passage 16 in repetition 2.
CONTROLS
-Positive control: cinnamaldehyde (CAS 104-55-2; batch no MKBT8955V; purity 99.1%)
-Negative (solvent) control: DMEM 1 g/l glucose, 1% DMSO, 1% non-heat inactivated foetal calf serum.
CELLS SEEDING.
-Culture plates: 5; 3 white cell culture plates (96 wells) for luminescence reading (induction measurement) + 2 transparent cell culture plates (96 wells) for absorbance reading (cytotoxicity).
-Cells suspension: 125 µl at 8x10e4 cells/ml in seeding medium were distributed in the culture plates.
-Cell density: 10e4 cells per well.
-Incubation: the seeded plates were incubated 24 hours ± 1 hour at 37ºC, 5% CO2
PREPARATION OF THE TEST ITEM AND CONTROL SUBSTANCES.
Test item solution: 2000 µM (1X) in treatment medium 1% DMSO
Positive control stock solution: The positive control was prepared at 200 mM in DMSO then diluted to the final concentration of 6.4 mM.
1) 100 X plate (positive and negative control): A 100-fold concentrated dilutions series was prepared in 96-well plate:
-Positive control: 100 µl of DMSO were distributed in row G from columns 7 to 10. 200 µl of the 6.4 mM stock solution were placed in column 11 then the series dilutions were prepared by transferring 100 µl of the column 11 in the column 10 and so on until the column 7. Dilutions were mixed by repeated pipetting, at least 3 times, between each concentration.
-Negative control: 100 µl of DMSO were distributed in row G columns 1 to 6 and 12 and in the well H12 (in cytotoxicity repetition 2, negative control was distributed in row H).
2) 4X dilution plate (positive and negative control): The 100 X plate was diluted 25 fold in a new plate (4 X).
3) Preparation of the 1X dilution for the test item:
The test item was placed in the row C.
1100 µl of treatment medium, 1% DMSO were distributed columns 1 to 10 in a masterblock. 2200 µl of the 2000 µM solution were placed in column 12 then the series dilutions were prepared by transferring 1100 µl of the column 12 in the column 11 and so until the column 1. Dilutions were mixed by repeated pipetting at least 3 times, between each concentration.
CONCENTRATIONS TESTED
-Test item: 12 concentrations according to a geometric progression of ratio 2 from 0.98 µM to 2000 µM.
-Positive control: 5 concentrations according to a geometric progression of ratio 2 from 4 to 64 µM.
APPLICATION OF THE TEST ITEM AND CONTROL SUBSTANCES
-Negative and positive control: In the 5 seeded plates, the medium was aspirated and replaced with 150 µl of treatment medium. Then the 4 X plate was replicated 5 times: 50 µl from the 4 X plate were placed in each of the three white plates and in the two transparent plates. The plates (1 X) were covered with an adhesive plastic foil to prevent evaporation and incubated for 48 hours ± 1 hour (37ºC, 5% CO2).
-Test item: In the 5 seeded plates, the medium was aspirated. The 1X masterblock was replicated 5 times: 200 µl from the 1X masterblock were placed in each of the three white plates and in the two transparent plates. The plates (1X) were covered with an adhesive plastic foil to prevent evaporation and incubated for 48 hours ± 1 hour (37ºC ± 1°C, 5% CO2).
REPLICATES: The study was composed of two independent repetitions. For each repetition the test item and the reference items were replicated on three independent plates for the measurement of induction and two plates for the measurement of cytotoxicity. Each repetition was performed on a different day with fresh stock solution.
LUCIFERASE ACTIVITY.
-Apparatus: Luminometer: GloMax™ (Promega)
-Validity of luminometer: validated according to the procedure described in Annex 3 of the OECD 442D guideline.
-Luciferase substrate: luciferine + ATP + lysing agent. Bright Glo™ Luciferase Assay System (Promega).
-Procedure: After 48 hours, the medium was aspirated and each well was gently washed once with 200 µl of PBS. Then 100 µl of luciferase substrate were then added in each well. The plates were incubated at least 15 minutes at room temperature to ensure cells lysis. The plates were placed in the luminometer then the luciferase activity was measured with an integration time of 2 seconds.
CITOTOXICITY ASSESSMENT.
-Apparatus: MULTISKAN EX plate reader (Thermo life sciences) - reading range 0 - 3.5 units of Absorbance -linearity range 0 - 2.200 units of Absorbance.
-Procedure: After 48 hours, the medium was aspirated and each well was gently washed once with 200 µl of PBS. Then, 225 µl of staining solution diluted at 0.6 mg/ml in treatment medium (from the 5mg/ml stock solution) were distributed in each well. The plates were covered with an adhesive plastic foil and incubated for 4 hours ± 30 minutes (37ºC, 5% CO2). After this contact time, the staining solution was eliminated and the cells were treated with 200 µl of 10% SDS (sodium dodecyl sulfate) a weekend in the dark (37°C, 5% CO2). After a 10 minutes homogenization, the absorbance was measured at 540 nm.
DEVIATIONS FROM OECD GUIDELINE:
The dilution strategy is different from the OECD 442D TG (paragraph 22). Given the slight solubility of the test item in water (i.e. 740 mg/l / 4.79 mM), the dilution was prepared directly 1X in treatment medium-1% DMSO at 2000 µM. This has no impact on the study result because the test item was tested in the expected final condition (i.e. 2000 µM as maximal concentration). - Positive control results:
- Repetition 1: The maximal average induction of luciferase activity (Imax) was 7.90 at a concentration of 64 µM. The mean value EC1.5 was 8.24 µM.
Repetition 2: The maximal average induction of luciferase activity (Imax) was 2.98 at a concentration of 64 µM. The mean value EC1.5 was 19.12 µM. - Key result
- Run / experiment:
- other: Repetition 1
- Parameter:
- other: Imax
- Value:
- 2.17
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Run / experiment:
- other: Repetition 2
- Parameter:
- other: Imax
- Value:
- 1.59
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Run / experiment:
- other: Repetition 1
- Parameter:
- other: EC1.5 (µM)
- Value:
- 629.89
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- (EC1.5 > IC30)
- Key result
- Run / experiment:
- other: Repetition 2
- Parameter:
- other: EC1.5 (µM)
- Value:
- 728.54
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- (EC1.5 > IC30)
- Key result
- Run / experiment:
- other: Repetition 1
- Parameter:
- other: IC30 (µM)
- Value:
- 523.9
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- (EC1.5 > IC30)
- Key result
- Run / experiment:
- other: Repetition 2
- Parameter:
- other: IC30 (µM)
- Value:
- 523.67
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- (EC1.5 > IC30)
- Other effects / acceptance of results:
- OTHER EFFECTS:
- Visible damage on test system: No
DEMONSTRATION OF TECHNICAL PROFICIENCY: yes, the 10 proficiency substances recommended in the OECD guideline 442D were performed, obtaining values that fall within the respective reference range for 8 out of the 10.
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: yes, the CV of the luminescence readings for repetition 1 was 13.6% and for repetition 2 was 9.0% which are less than 20%.
- Acceptance criteria met for positive control: Yes, the luciferase activity induction was statistically significant above the threshold of 1.5 in at least one dose tested for each repetition. The average induction values at 64 µM were 7.90 and 2.98 in each repetition which are between 2 and 8. The EC1.5 values were 8.24 and 19.12 µM for each repetition which are within 2 SD of the historical mean of the testing facility and between 7 µM and 30 µM based on the OECD validation dataset. - Interpretation of results:
- other: KeratinoSensTM test result is considered in an overall weight of evidence assessment, i.e. as part of an integrated approach to testing and assessment (IATA) in accordance with OECD guideline 442D.
- Conclusions:
- Under the experimental conditions the test item L-borneol may be classified as not skin sensitizer using the KeratinoSensTM test method.
- Executive summary:
The KeratinoSensTM test method was performed for L-borneol as part of an integrated approach to testing and assessment (IATA) in accordance to OECD guideline 442D, under GLP conditions. A KeratinoSensTM cell culture was prepared, incubated for 24 hours ± 1 hour at 37ºC, 5% CO2 and distributed into 3 plates (96 wells) for the measurement of the induction of luciferase activity and 2 plates (96 wells) to assess the cytotoxicity. Test item at 12 concentrations from 0.98 µM to 2000 µM, positive control cinnamaldehyde at 5 concentrations from 4 to 64 µM and negative control 1% DMSO were placed in the seeded plates and incubated for 48 hours ± 1 hour at 37ºC, 5% CO2. 2 repetitions were performed on a different day with fresh stock solution. All validity criteria were fulfilled. For the test item, calculated Imax values were higher than 1.5 but at EC1.5 concentration the reduction of viability was determined higher than 30% (i.e. EC1.5 > IC30), thus a negative result can be predicted for skin sensitization using the KeratinoSensTM test method.
Referenceopen allclose all
Table 3: Positive control
Cinnamaldehyde |
Depletion in Lysine Peptide % |
Depletion in Cysteine Peptide % |
Repetition 1 |
56.06 |
73.71 |
Repetition 2 |
55.31 |
73.73 |
Repetition 3 |
55.32 |
74.14 |
SD (Standard Deviation) |
0.430 |
0.243 |
Mean |
55.56 |
73.86 |
Depletion Validity criteria |
40.2 < Depletion < 69.4 |
60.8 < Depletion < 100 |
CV |
0.77% |
0.33% |
Table 4: Test item
|
Depletion in Lysine Peptide % |
Depletion in Cysteine Peptide % |
|
Repetition 1 |
0.21 |
0 |
|
Repetition 2 |
0.91 |
1.79 |
Mean Depletion % |
Repetition 3 |
1.78 |
2.08 |
|
Mean |
0.97 |
1.29 |
1.13 |
SD (Standard Deviation) |
0.78 |
1.13 |
|
SD Validity criteria |
< 11.6% |
< 14.9% |
|
No co-elution occurred of the test item neither with lysine nor with cysteine peptides
Table 1: Positive control
Cinnamaldehyde |
4 µM |
8 µM |
16 µM |
32 µM |
64 µM |
EC1.5 |
Imax |
Rep 1 |
1.37 |
1.48 |
2.22 |
3.66 |
7.90 |
8.24 |
7.90 |
Rep 2 |
1.15 |
1.19 |
1.22 |
2.67 |
2.98 |
19.12 |
2.98 |
Mean |
1.26 |
1.33 |
1.72 |
3.17 |
5.44 |
12.55* |
5.44 |
*geometric mean |
Table 2: Test item
VIABILITY |
INDUCTION |
||||
IC30(µM) |
IC50(µM) |
Imax |
Linear EC1.5 (µM) |
EC1.5 Lin/Log (µM) |
|
Rep 1 |
523.90 |
>2000 |
2.17 |
629.89 |
598.65 |
Rep 2 |
523.67 |
>2000 |
1.59 |
728.54 |
686.38 |
Mean |
- |
- |
1.88 |
- |
- |
Geometric mean |
523.79 |
>2000 |
- |
677.42 |
641.02 |
Table 3: Test item mean viability percentage
Concentration µM |
0,98 |
1,95 |
3,91 |
7,81 |
15,6 |
31,3 |
63 |
125 |
250 |
500 |
1000 |
2000 |
Rep 1 |
77,28 |
85,07 |
82,78 |
86,75 |
89,27 |
77,05 |
80,72 |
69,34 |
70,87 |
70,33 |
63,38 |
50,25 |
Rep 2 |
101,33 |
100,85 |
91,61 |
94,95 |
83,40 |
84,60 |
88,74 |
83,01 |
81,89 |
70,26 |
64,76 |
57,43 |
Viability |
89,30 |
92,96 |
87,19 |
90,85 |
86,34 |
80,83 |
84,73 |
76,17 |
76,38 |
70,30 |
64,07 |
53,84 |
Table 4: Test item mean induction
Concentration µM |
0,98 |
1,95 |
3,91 |
7,81 |
15,63 |
31,25 |
62,50 |
125 |
250 |
500 |
1000 |
2000 |
Rep 1 |
1,07 |
1,15 |
1,13 |
1,29 |
1,15 |
1,17 |
1,21 |
1,28 |
1,38 |
1,42 |
1,74 |
2,17 |
Rep 2 |
1,00 |
1,20 |
1,13 |
1,15 |
1,30 |
1,30 |
1,20 |
1,27 |
1,30 |
1,42 |
1,59 |
1,37 |
Induction |
1,04 |
1,18 |
1,13 |
1,22 |
1,22 |
1,24 |
1,20 |
1,28 |
1,34 |
1,42 |
1,66 |
1,77 |
SD |
0,05 |
0,03 |
0,00 |
0,10 |
0,11 |
0,09 |
0,01 |
0,01 |
0,06 |
0,00 |
0,10 |
0,57 |
Table 5: Student t-test
Rep 1 |
0,492 |
0,452 |
0,302 |
0,041 |
0,114 |
0,170 |
0,091 |
0,014 |
0,014 |
0,006 |
0,014 |
0,014 |
Rep 2 |
0,984 |
0,018 |
0,015 |
0,029 |
0,055 |
0,039 |
0,003 |
0,001 |
0,007 |
0,007 |
0,001 |
0,001 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Skin sensitisation (in chemico): Weight of evidence. A DPRA skin sensitization test was performed for L-borneol as part of an integrated approach to testing and assessment (IATA) in accordance to OECD guideline 442C, under GLP conditions. The test item and Cinnamaldehyde (positive control) were prepared at 100 mM in acetonitrile as solvent. Reference controls A, B and C were prepared with acetonitrile in order to check the HPLC system suitability, the stability of peptide over time and the influence of the solvent on the peptide depletion respectively. Peptide solutions were prepared at 0.667 mM in phosphate buffer for cysteine and ammonium acetate buffer for lysine. Test item and positive control were incubated for 24 hours ± 2 hours at 25°C± 2.5°C with the peptides solutions at 1:10 and 1:50 ratio for cysteine and lysine respectively, before HPLC analysis. Each sample was tested 3 times from 3 independent solutions. All validity criteria were fulfilled. The test item shows mean depletion of 0.97% for lysine and 1.29% for cysteine, i.e. an overall average of 1.13%, reflecting no or minimal reactivity and thus a negative prediction of DPRA.
Skin sensitisation (in vitro): Weight of evidence. The KeratinoSensTM test method was performed for L-borneol as part of an integrated approach to testing and assessment (IATA) in accordance to OECD guideline 442D, under GLP conditions. A KeratinoSensTM cell culture was prepared, incubated for 24 hours ± 1 hour at 37ºC, 5% CO2 and distributed into 3 plates (96 wells) for the measurement of the induction of luciferase activity and 2 plates (96 wells) to assess the cytotoxicity. Test item at 12 concentrations from 0.98 µM to 2000 µM, positive control cinnamaldehyde at 5 concentrations from 4 to 64 µM and negative control 1% DMSO were placed in the seeded plates and incubated for 48 hours ± 1 hour at 37ºC, 5% CO2. 2 repetitions were performed on a different day with fresh stock solution. All validity criteria were fulfilled. For the test item, calculated Imax values were higher than 1.5 but at EC1.5 concentration the reduction of viability was determined higher than 30% (i.e. EC1.5 > IC30), thus a negative result can be predicted for skin sensitization using the KeratinoSensTM test method.
Skin sensitisation: Weight of evidence. integrated testing strategy (ITS). Based on the OECD Guidance Document on the reporting of defined approaches to be used within integrated approaches to testing and assessment for skin sensitization ((ENV/JM/MONO(2016)29), the “2 out of 3-sens ITS” approach as described in its annex 1 has been selected to allow the classification of the substance.
The combination of test methods used in this strategy covers the first three key events (KEs) of the adverse outcome pathway (AOP) leading to skin sensitisation as formally described by the OECD: KE 1: protein binding (e.g. via the direct peptide reactivity assay (DPRA); OECD TG 442C); KE 2: keratinocyte activation (e.g. via the KeratinoSensTM or LuSens assay; OECD TG 442D); and dendritic cell activation [e.g. via the human cell line activation test (h-CLAT); OECD TG 442E or the modified Myeloid U937 Skin Sensitisation Test (mMUSST)].
As there is no differential weighting of the individual test methods used and no predefined sequential order of testing, the order and information source from which data is obtained is not defined. Due to the higher complexity and resources needed (e.g. flow cytometer needed) to conduct the tests used for KE 3, the DPRA (KE1) and Nrf2-ARE-based tests (KE2) will usually be conducted first.
Based on the current knowledge, information obtained from peptide reactivity, whether obtained from in chemico or in silico methods, seems to show the highest predictive power and may provide more weight to the overall assessment of skin sensitisation (Natsch et al., 2013, Urbisch et al., 2015).
According to this approach two concordant results addressing two different key events (KEs) indicate the sensitising potential, i.e. two positive results indicate a sensitiser, two negative results indicate a non-sensitiser.
Thus, L-borneol does not need to be classified as skin sensitizer.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available data, the substance is not classified for skin sensitization according to CLP Regulation no. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)